In vitro susceptibility of established biofilms composed of a clinical wound isolate of Pseudomonas aeruginosa treated with lactoferrin and xylitol

International Journal of Antimicrobial Agents

Volumn 33, Issue 3, 2009, Pages 230-236

  Ammons, Mary Cloud B ^a   Ward, Loren S ^b   Fisher, Steve T ^a   Wolcott, Randall D ^c   James, Garth A ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b Glanbia Innovation Centre   (Ireland)

^c Southwest Regional Wound Care Center Lubbock   (United States)

Author keywords

Biofilm; Lactoferrin; Pseudomonas aeruginosa; Xylitol

Indexed keywords

LACTOFERRIN; XYLITOL;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL MEMBRANE; BACTERIAL VIABILITY; BACTERIUM ISOLATION; BIOFILM; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; WOUND;

ANTI-BACTERIAL AGENTS; BIOFILMS; CELL MEMBRANE PERMEABILITY; DRUG SYNERGISM; HUMANS; LACTOFERRIN; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; WOUND INFECTION; XYLITOL;

EID: 60249083329     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.08.013     Document Type: Article

References (44)

1. James G.A., Swogger E., Wolcott R., Pulcini E.D., Secor P., Sestrich J., et al. Biofilms in chronic wounds. Wound Repair Regen 16 (2008) 37-44
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diab Care 2008;31:596-615. Erratum in: Diab Care 2008;31:1271.
3. Gottrup F. A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg 187 5A (2004) 38S-43S
4. McGuckin M., Goldman R., Bolton L., and Salcido R. The clinical relevance of microbiology in acute and chronic wounds. Adv Skin Wound Care 16 (2003) 12-23 quiz 24-5
5. Bjarnsholt T., Kirketerp-Moller K., Jensen P.O., Madsen K.G., Phipps R., Krogfelt K., et al. Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen 16 (2008) 2-10
6. Konturek P.C., Brzozowski T., Konturek S.J., Kwiecien S., Dembinski A., and Hahn E.G. Influence of bacterial lipopolysaccharide on healing of chronic experimental ulcer in rat. Scand J Gastroenterol 36 (2001) 1239-1247
7. Power C., Wang J.H., Sookhai S., Street J.T., and Redmond H.P. Bacterial wall products induce downregulation of vascular endothelial growth factor receptors on endothelial cells via a CD14-dependent mechanism: implications for surgical wound healing. J Surg Res 101 (2001) 138-145
8. Costerton J.W., Stewart P.S., and Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 284 (1999) 1318-1322
9. Donlan R.M., and Costerton J.W. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15 (2002) 167-193
10. Parsek M.R., and Singh P.K. Bacterial biofilms: an emerging link to disease pathogenesis. Ann Rev Microbiol 57 (2003) 677-701
11. Saye D.E. Recurring and antimicrobial-resistant infections: considering the potential role of biofilms in clinical practice. Ostomy Wound Manage 53 (2007) 46-48 50, 52 passim
12. Edwards R., and Harding K.G. Bacteria and wound healing. Curr Opin Infect Dis 17 (2004) 91-96
13. Gjodsbol K., Christensen J.J., Karlsmark T., Jorgensen B., Klein B.M., and Krogfelt K.A. Multiple bacterial species reside in chronic wounds: a longitudinal study. Int Wound J 3 (2006) 225-231
14. Dowd S.E., Sun Y., Secor P.R., Rhoads D.D., Wolcott B.M., James G.A., et al. Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiol 8 (2008) 43
15. Ceri H., Olson M.E., Stremick C., Read R.R., Morck D., and Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37 (1999) 1771-1776
16. Singh P.K., Parsek M.R., Greenberg E.P., and Welsh M.J. A component of innate immunity prevents bacterial biofilm development. Nature 417 (2002) 552-555
17. Valenti P., Berlutti F., Conte M.P., Longhi C., and Seganti L. Lactoferrin functions: current status and perspectives. J Clin Gastroenterol 38 6 Suppl (2004) S127-S129
18. Weinberg E.D. Human lactoferrin: a novel therapeutic with broad spectrum potential. J Pharm Pharmacol 53 (2001) 1303-1310
19. Cohen M.S., Mao J., Rasmussen G.T., Serody J.S., and Britigan B.E. Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J Infect Dis 166 (1992) 1375-1378
20. Oseas R., Yang H.H., Baehner R.L., and Boxer L.A. Lactoferrin: a promoter of polymorphonuclear leukocyte adhesiveness. Blood 57 (1981) 939-945
21. Valenti P., Greco R., Pitari G., Rossi P., Ajello M., Melino G., et al. Apoptosis of Caco-2 intestinal cells invaded by Listeria monocytogenes: protective effect of lactoferrin. Exp Cell Res 250 (1999) 197-202
22. Orsi N. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 17 (2004) 189-196
23. Stephens S., Dolby J.M., Montreuil J., and Spik G. Differences in inhibition of the growth of commensal and enteropathogenic strains of Escherichia coli by lactotransferrin and secretory immunoglobulin A isolated from human milk. Immunology 41 (1980) 597-603
24. Dolby J.M., and Stephens S. Antibodies to Escherichia coli O antigens and the in-vitro bacteriostatic properties of human milk and its IgA. Acta Paediatr Scand 72 (1983) 577-582
25. Rainard P. Activation of the classical pathway of complement by binding of bovine lactoferrin to unencapsulated Streptococcus agalactiae. Immunology 79 (1993) 648-652
26. Granstrom T.B., Izumori K., and Leisola M. A rare sugar xylitol. Part II: biotechnological production and future applications of xylitol. Appl Microbiol Biotechnol 74 (2007) 273-276
27. Katsuyama M., Ichikawa H., Ogawa S., and Ikezawa Z. A novel method to control the balance of skin microflora. Part 1. Attack on biofilm of Staphylococcus aureus without antibiotics. J Dermatol Sci 38 (2005) 197-205
28. Kim J., Pitts B., Stewart P.S., Camper A., and Yoon J. Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. Antimicrob Agents Chemother 52 (2008) 1446-1453
29. Jefferson K.K. What drives bacteria to produce a biofilm?. FEMS Microbiol Lett 236 (2004) 163-173
30. Carpentier B., and Cerf O. Biofilms and their consequences, with particular reference to hygiene in the food industry. J Appl Bacteriol 75 (1993) 499-511
31. Hatch R.A., and Schiller N.L. Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother 42 (1998) 974-977
32. Dunne Jr. W.M. Bacterial adhesion: seen any good biofilms lately?. Clin Microbiol Rev 15 (2002) 155-166
33. Lawrence J.R., Korber D.R., Hoyle B.D., Costerton J.W., and Caldwell D.E. Optical sectioning of microbial biofilms. J Bacteriol 173 (1991) 6558-6567
34. Stewart J.A., Silimperi D., Harris P., Wise N.K., Fraker Jr. T.D., and Kisslo J.A. Echocardiographic documentation of vegetative lesions in infective endocarditis: clinical implications. Circulation 61 (1980) 374-380
35. Singh P.K. Iron sequestration by human lactoferrin stimulates P. aeruginosa surface motility and blocks biofilm formation. Biometals 17 (2004) 267-270
36. Psaltis A.J., Wormald P.J., Ha K.R., and Tan L.W. Reduced levels of lactoferrin in biofilm-associated chronic rhinosinusitis. Laryngoscope 118 (2008) 895-901
37. Ellison III R.T., Giehl T.J., and LaForce F.M. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun 56 (1988) 2774-2781
38. Dial E.J., and Lichtenberger L.M. Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol 80 (2002) 113-117
39. Erdei J., Forsgren A., and Naidu A.S. Lactoferrin binds to porins OmpF and OmpC in Escherichia coli. Infect Immun 62 (1994) 1236-1240
40. Hrimech M., Mayrand D., Grenier D., and Trahan L. Xylitol disturbs protein synthesis, including the expression of HSP-70 and HSP-60, in Streptococcus mutans. Oral Microbiol Immunol 15 (2000) 249-257
41. Trahan L., and Mouton C. Selection for Streptococcus mutans with an altered xylitol transport capacity in chronic xylitol consumers. J Dent Res 66 (1987) 982-988
42. Vogel L., Geluk F., Jansen H., Dankert J., and van Alphen L. Human lactoferrin receptor activity in non-encapsulated Haemophilus influenzae. FEMS Microbiol Lett 156 (1997) 165-170
43. Trahan L., Soderling E., Drean M.F., Chevrier M.C., and Isokangas P. Effect of xylitol consumption on the plaque-saliva distribution of mutans streptococci and the occurrence and long-term survival of xylitol-resistant strains. J Dent Res 71 (1992) 1785-1791
44. Wolcott R.D., and Rhoads D.D. A study of biofilm-based wound management in subjects with critical limb ischaemia. J Wound Care 17 (2008) 145-148 150-2, 154-5